Cleared Traditional

K220001 - Diazyme Human Kappa Free Light Chain Assay, Diazyme Human Lambda Free Light Chain Assay (FDA 510(k) Clearance)

Aug 2022
Decision
212d
Days
Class 2
Risk

K220001 is an FDA 510(k) clearance for the Diazyme Human Kappa Free Light Chain Assay, Diazyme Human Lambda Free Light Chain Assay. This device is classified as a Kappa, Antigen, Antiserum, Control (Class II - Special Controls, product code DFH).

Submitted by Diazyme Laboratories, Inc. (Poway, US). The FDA issued a Cleared decision on August 4, 2022, 212 days after receiving the submission on January 4, 2022.

This device falls under the Immunology FDA review panel. Regulated under 21 CFR 866.5550.

Submission Details

510(k) Number K220001 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 04, 2022
Decision Date August 04, 2022
Days to Decision 212 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement

Device Classification

Product Code DFH — Kappa, Antigen, Antiserum, Control
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.5550